Ed Dybka

Ed Dybka was appointed to the role of General Manager at Ipsen Biopharmaceuticals Canada Inc. in 2018. In this role, he is responsible for overseeing all of Ipsen’s operations across all therapeutic areas in Canada. Ed is a member of the Ipsen North America Leadership Team and the Ipsen Global Leadership Team.

Ed has a wealth of experience and has made a significant contribution to the Canadian Life Sciences industry with over 30 years in the pharmaceutical industry within the Canadian market. Prior to joining Ipsen, Ed was the President & CEO of AstraZeneca Canada Inc., part of AstraZeneca PLC, one of the world’s leading biopharmaceutical companies

In 2012, Ed led the Canadian establishment of Almirall, a start-up biopharmaceutical company focused on the treatment of respiratory diseases. Prior to establishing Almirall in Canada, Ed held a number of executive roles at GlaxoSmithKline Canada including Vice President of Marketing, Sales and Public Affairs & Reimbursement. During this time, he was accountable for the marketing and sales of all GSK pharmaceutical products, including specialty care, oncology and vaccines, achieving strong commercial performance and employee engagement.

In addition to his role at Ipsen, Ed is currently on the Board of Directors for Innovative Medicines Canada. Throughout his career he has been committed to advancing Life Sciences in Canada including his roles on the Board of Directors of Life Sciences Ontario, Clinical Trials Ontario, The Acute Coronary Treatment Foundation, The Pharmaceutical Advertising Advisory Board ( PAAB) and recently as a member of the Health & Biosciences Economic Strategy Table for the Federal Ministry of Health and Ministry of Innovation, Science and Economic Development.